Wuerzburg

• Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting
  2022-500013-32-01 5 2024-07-05 Adrenocortical carcinoma
• A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting
  2023-508590-89-00 7 2024-06-25 Multiple Myeloma
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit … Recruiting
  2022-502404-73-00 4 2024-06-03 Pancreatic ductal adenocarcinoma
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum … Recruiting
  2023-507751-30-00 9 2024-05-27 relapsed or refractory multiple myeloma
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies Recruiting
  2022-501648-14-00 9 2024-05-05 Relapsed or refractory CD19 positive B cell malignancies (adult ALL, a
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• European Larynx Organ Preservation Study (ELOS) Recruiting
  2022-502751-61-00 4 2024-04-10 Advanced stage III, IVA, IVB laryngeal or II, III, IVA, IVB hypopharyn
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 4 2024-04-08 Mantle Cell Lymphoma (MCL)
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho … Recruiting
  2023-505141-48-00 5 2024-03-07 Fibrosis
• Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome Recruiting
  2023-503327-26-00 5 2024-01-31 Sjogren's syndrome
• A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in … Recruiting
  2022-501941-63-00 7 2023-12-13 Multiple myeloma
• Intravenous Fish Oil based Lipid Emulsion to enhance recovery in High-Risk Cardiac Surgery Patients: a phase II multicenter trial Recruiting
  2023-503490-38-00 4 2023-11-15 critical illness, intensive care unit (ICU), surgery
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: … Recruiting
  2023-503558-10-00 5 2023-10-13 oligometastatic pancreatic cancer
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 5 2023-10-02 Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient … Recruiting
  2022-501810-77-00 5 2023-09-01 Relapsed or Refractory Marginal Zone Lymphoma
• A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatr … Recruiting
  2024-511336-28-00 9 2023-08-11 Leukemia in childhood
• A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag … Recruiting
  2022-503133-54-00 7 2023-08-09 Solid Tumors
• Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Recruiting
  2022-501797-19-00 1 2023-07-13 Acute Myeloid Leukemia (AML)
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 4 2023-07-13 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
• Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study … Recruiting
  2024-514022-23-00 4 2023-06-23 Early breast cancer

Showing 145–168 of 430 trials